| Title |
Orchestrating epigenetic roles targeting ocular tumors
|
|---|---|
| Published in |
OncoTargets and therapy, February 2016
|
| DOI | 10.2147/ott.s93995 |
| Pubmed ID | |
| Authors |
Xuyang Wen, Linna Lu, Zhang He, Xianqun Fan |
| Abstract |
Epigenetics is currently one of the most promising areas of study in the field of biomedical research. Scientists have dedicated their efforts to studying epigenetic mechanisms in cancer for centuries. Additionally, the field has expanded from simply studying DNA methylation to other areas, such as histone modification, non-coding RNA, histone variation, nucleosome location, and chromosome remodeling. In ocular tumors, a large amount of epigenetic exploration has expanded from single genes to the genome-wide level. Most importantly, because epigenetic changes are reversible, several epigenetic drugs have been developed for the treatment of cancer. Herein, we review the current understanding of epigenetic mechanisms in ocular tumors, including but not limited to retinoblastoma and uveal melanoma. Furthermore, the development of new pharmacological strategies is summarized. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 4% |
| Denmark | 1 | 4% |
| Unknown | 26 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 18% |
| Student > Master | 5 | 18% |
| Other | 4 | 14% |
| Professor | 4 | 14% |
| Student > Ph. D. Student | 3 | 11% |
| Other | 3 | 11% |
| Unknown | 4 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 29% |
| Biochemistry, Genetics and Molecular Biology | 6 | 21% |
| Agricultural and Biological Sciences | 5 | 18% |
| Nursing and Health Professions | 1 | 4% |
| Psychology | 1 | 4% |
| Other | 3 | 11% |
| Unknown | 4 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2016.
All research outputs
#15,049,705
of 25,584,565 outputs
Outputs from OncoTargets and therapy
#754
of 3,012 outputs
Outputs of similar age
#202,542
of 407,569 outputs
Outputs of similar age from OncoTargets and therapy
#31
of 95 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,012 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 407,569 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.